A comprehensive genomic study has identified distinct mutational signatures in normal blood cells correlated with exposure to 21 different chemotherapy drugs. Led by the Wellcome Sanger Institute and University of Cambridge, this research elucidates how specific agents, such as carboplatin, induce extensive DNA damage in healthy tissues, possibly contributing to long-term side effects and secondary malignancies. These findings may guide future chemotherapy selection to minimize harm while maintaining efficacy.